Hims & Hers Health, Inc. HIMS R2KR3KPHARMA
Company Overview
Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, skincare, sexual health and wellness, and hair care under the Hims & Hers brand name; and laboratory testing services to measure a set of biomarkers. Additionally, it offers medical consultation, post-consultation support services, and delivery of laboratory testing results services. Further, the company provides treatments and products for various chronic conditions related to hormone health, weight loss, dermatology, and mental health. The company offers its products through retail partnerships, in stores, and online. Hims & Hers Health, Inc. is based in San Francisco, California.
Why Investors Should Care
Revenue has grown at a 74.7% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $2.35B (+59.0% YoY); net profit $128.37M.
- Trailing 12 Months Year-on-year growth — revenue +3.8%, earnings +1.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 74.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 74.71% |
| 1 Year: | 3.80% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | 1.85% |
Stock Price Performance
| 1 Year: | -42.67% |
| 6 Months: | +76.05% |
| 3 Months: | +5.80% |
| 1 Month: | -6.57% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)43.34 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 74.7% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 55.9% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | HIMS Hims & Hers Health, Inc. R2KR3KPHARMA | 27.71 | -307.89 | $6.18B | 0.00% | 6.03% | -2.66% | 74.71% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 30.06M | 35.90M | 41.32M | 52.31M | 60.69M | 74.17M | 101.31M | 113.56M | 144.84M | 190.77M | 207.91M | 226.70M | 278.17M | 315.65M | 401.56M | 586.01M | 544.83M | 598.98M | 608.10M | 753.21M |
| Gross Profit | - | - | 20.62M | 25.66M | 31.28M | 40.25M | 47.28M | 54.87M | 74.76M | 87.18M | 114.45M | 153.43M | 170.16M | 187.31M | 229.09M | 256.61M | 317.89M | 430.69M | 416.20M | 442.06M | 396.79M | 480.80M |
| Operating Income | -16.61K | -449.94K | -6.22M | -979.00K | -3.32M | -48.41M | -17.41M | -27.66M | -16.92M | -20.19M | -19.98M | -11.26M | -9.24M | -8.55M | 9.90M | 11.03M | 22.37M | 57.90M | 26.72M | 11.81M | -78.32M | -97.19M |
| Net Income | -16.61K | 436.05K | -6.03M | -981.00K | -5.87M | -51.40M | -9.15M | -15.94M | -16.25M | -19.68M | -18.84M | -10.07M | -7.16M | -7.57M | 11.13M | 13.30M | 75.59M | 49.48M | 42.51M | 15.77M | -92.11M | -86.29M |
| Diluted EPS | - | - | -0.17 | -0.03 | -0.16 | -0.34 | -0.05 | -0.08 | -0.08 | -0.10 | -0.09 | -0.05 | -0.03 | -0.04 | 0.05 | 0.06 | 0.32 | 0.20 | 0.17 | 0.06 | -0.40 | -0.37 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 82.56M | 148.76M | 271.88M | 526.92M | 872.00M | 1.48B | 2.35B |
| Gross Profit | 44.60M | 109.45M | 204.49M | 408.72M | 714.95M | 1.17B | 1.73B |
| Operating Income | -74.41M | -15.14M | -115.04M | -68.70M | -29.45M | 61.90M | 105.61M |
| Net Income | -72.06M | -18.11M | -107.66M | -65.68M | -23.55M | 126.04M | 128.37M |
| Diluted EPS | -2.07 | -0.51 | -0.58 | -0.32 | -0.11 | 0.53 | 0.51 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Apr 2019 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 204.77M | 118.70M | - | 366.34M | 441.19M | 707.54M | 2.15B |
| Current Assets | - | - | - | - | - | 216.59M | 265.05M | 395.83M | 767.64M |
| Cash & Equivalents | - | - | 1.51M | 27.34M | - | 46.77M | 96.66M | 220.58M | 228.62M |
| Inventory | - | - | - | - | - | 21.56M | 22.46M | 64.43M | 80.13M |
| Receivables | - | - | - | - | - | 3.23M | 6.75M | 6.08M | 32.15M |
| Total Liabilities | - | - | 8.17M | 15.61M | - | 54.60M | 97.16M | 230.82M | 1.61B |
| Current Liabilities | - | - | 979.39K | 15.23M | - | 47.94M | 88.47M | 221.37M | 404.43M |
| Long Term Debt | - | - | - | - | - | - | - | - | 972.58M |
| Total Debt | - | - | - | - | - | 5.31M | 9.95M | 11.35M | 1.12B |
| Total Equity | -71.36M | 0 | -139.79M | -146.87M | - | 311.74M | 344.03M | 476.72M | 540.93M |
| Shares Outstanding | - | - | - | - | - | 208.43M | 213.48M | 220.84M | 227.25M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -74.87M | -2.48M | - | -26.53M | 73.48M | 251.08M | 300.01M |
| Investing Cash Flow | -39.30M | -39.70M | - | 34.70M | -12.11M | -19.05M | -1.02B |
| Financing Cash Flow | 95.32M | 47.74M | - | -33.13M | -11.47M | -107.84M | 729.62M |
| Capital Expenditure | - | - | - | -7.25M | -26.49M | -52.75M | -242.59M |
| Free Cash Flow | - | - | - | -33.78M | 46.99M | 198.33M | 57.41M |
| Net Change in Cash | - | - | - | -24.96M | 49.90M | 124.19M | 4.67M |
| Share Buybacks | 0 | 0 | 0 | 0 | 2.00M | 83.04M | 89.96M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | 54.0% | 73.6% | 75.2% | 77.6% | 82.0% | 79.5% | 73.8% |
| Operating Margin % | -90.1% | -10.2% | -42.3% | -13.0% | -3.4% | 4.2% | 4.5% |
| Net Margin % | -87.3% | -12.2% | -39.6% | -12.5% | -2.7% | 8.5% | 5.5% |
| ROE % | 51.6% | 12.3% | - | -21.1% | -6.8% | 26.4% | 23.7% |
| ROCE % | -36.5% | -14.6% | - | -21.6% | -8.4% | 12.7% | 6.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 12.76% | 28.70M | $827.81M |
| 2 | Vanguard Portfolio Management LLC | 4.69% | 10.56M | $304.53M |
| 3 | Vanguard Capital Management LLC | 4.24% | 9.54M | $275.17M |
| 4 | State Street Corporation | 3.62% | 8.15M | $234.92M |
| 5 | Morgan Stanley | 3.18% | 7.15M | $206.28M |
| 6 | Divisadero Street Capital Management, LP | 2.67% | 6.01M | $173.31M |
| 7 | Geode Capital Management, LLC | 2.53% | 5.68M | $163.86M |
| 8 | Goldman Sachs Group Inc | 2.30% | 5.17M | $149.21M |
| 9 | JPMORGAN CHASE & CO | 2.12% | 4.77M | $137.47M |
| 10 | FMR, LLC | 1.92% | 4.32M | $124.68M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for HIMS
HIMS Stock Logs Best Day In 2 Months: Bull Sees Peptides Driving Up To $19B In Annual Revenue By 2030 - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxONnE1TWpudmliUjMyXzlocWY4S3o4ZExjS2E5S2RyRUg3X0xzNzR5ZGhPV0FZZHBydFQ2QW4wMnZWckM2dV85UEhUYTlXUW1QUlRoaDhGcUJEaW9kdTUtREIyVUEyXzRQMS14dEE2ODNHMXNoaGJuTmx1SGdZUFo3NU1KcC0wWDBERmNQSz…
Investors sue Hims & Hers after FTC lawsuit plummets stock price - courthousenews.com
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxNUEtwNWZYLWp2cnFWTy1vRlB2NF8xWXNhMGk5T2ZLck1mcDJaM0M3WkJucnFSdTN4Wjktc0xEaVZzRlI2VV9SVmd1WVdLWXZ6dHBKYlFvZ0ZMVFhSS3hTVkxfak5mamhLaHdZbU9rUkNMRWFDenJJT0VQWjhNTDdJZXdkTFJraVM0NktaWD…
HIMS Stock More Than Doubled in 6 Months: What's Driving the Rally? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxNdVhrUmYzZzFDdTF0dG9vdGhhWTNtQXhUcHR2blpJZThIaDQwSWdtT3hQd3pEbFBvTTNhY3puaHk2MzdzbjNtenIyWGFsNndlTnRBTzFnNUFqOHJTcm5rdktYRWtTMG9Cd01FOXlEUEFxM2tfTmktT1VOTlQyTFNUT1MzUmdWWFlIUUhWLW…
INVESTOR DEADLINE ALERT: Hims & Hers Health, Inc. (HIMS) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - PR Newswire
<a href="https://news.google.com/rss/articles/CBMilAJBVV95cUxOOHZJNTI3UlFHMFpvNzlSV0pGc0dFNHpGdlpDX1E5ZW82eE1ETS1kcVJXMzI5bmRpYkVrZ1BZckgxMnBmdVQ2Q2JRbkExZnpPZDg0d3lhSW9lWG9qRXQ2LTBacFY5a0Z6N1kwVktBajFhRzdYNUJHck5JWjJQa29zWGNidlMwdTVzWmE2YX…
Here's Why Teladoc's Integrated Care Business Deserves More Attention - TradingView
<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxORlR6dnFSblM2RjYwdHZJVFBpWGhUT2ZfZnBnQWZKS0pvdnVkNXFaQ216ejhfOG1LRDljYkloNU5KUGJTcURMSUJhc1ZEUGZDN2NldzRLMUR2R2J1eUhic2NUOU56MHJWc093aXBuSDhmOGVlMjRadzBZdEtVTHlaQWlraElIcEd1cWxQT0…
HIMS Stock Eyes Breakout Week: Eight New Partners Fuel Push To Build An All-In-One Health Platform - Stocktwits
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxQTmFzT1g5LXFvWnJjVGJqNUJWRHNqVTE5M09tOXJib0pSSU54dUxucGlDdGRpOFlYWEctZ2VMV09iVWdienRWTFY1Z2J1bWRoZ09ZZi1pVGRCZFo5eHg2aWRIbGNGa0dVcnNVVEJSOWRLSlB1cVItMWJaU0xrUXpnTlkwR0FjZGh0SUI2RX…
HIMS — Frequently Asked Questions
What is the current share price of Hims & Hers Health, Inc. (HIMS)?
As of 2026-09-07 16:24 PDT, Hims & Hers Health, Inc. (HIMS) trades at $27.71 on NYSE. Its 52-week range is $14.52 to $62.76.
What is the market capitalisation of HIMS?
Hims & Hers Health, Inc. (HIMS) has a market capitalisation of $6.18B on NYSE.
What is the P/E ratio of HIMS?
HIMS trades at a trailing price-to-earnings (P/E) ratio of -307.89. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 16.33.
What is the return on equity (ROE) of HIMS?
HIMS has a return on equity (ROE) of -2.66%. Its return on capital employed (ROCE) is 6.03%.
Is HIMS a good stock to buy?
This page provides a data-driven analysis of Hims & Hers Health, Inc. (HIMS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.